The Hunter syndrome space suffered a setback in February when the FDA turned down REGENXBIO's investigational gene therapy, ...
They might develop some seriously expensive taste! One Ragdoll cat recently got her first taste of sashimi, and it seems like ...
Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines in areas of high unmet need in rare muscle diseases, ...
Zinc supplements are widely used to boost immunity and treat deficiencies, but taking too much can cause nausea, nutrient ...
What Is Loargys, and Why Does It Matter? Loargys is an enzyme-based medicine that has been granted accelerated approval by the FDA for managing high levels of the amino acid arginine (hyperargininemia ...
12d
A CT man died not long after starting chemotherapy. What his family believes could have saved him.
Then Brian McCutcheon died on Nov. 3, 2023, allegedly as a result of the chemotherapy medications he received to treat cancer ...
Our bodies perform many critical metabolic reactions, using a wide range of enzymes and other molecules. When there is a ...
A new study suggests that suppressing a cellular enzyme long considered protective against fatty liver disease could have unexpected long-term consequences.
ARG1-D is an ultra-rare, debilitating, and progressive metabolic disease resulting in persistent elevation of plasma arginine, also known as hyperargininemia FDA accelerated approval of LOARGYS is ...
LOARGYS is the first and only therapy proven to lower arginine in patients 2 years of age and older living with ARG1-D ARG1-D is an ultra-rare, debilitating, and progressive metabolic disease ...
New review highlights evolving Pompe disease management, from screening to next-generation therapies and monitoring. Read ...
The therapy shows efficacy in improving diarrhea, abdominal pain in GLP-1, GLP-1/GIP-treated patients with diabetes and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results